• Analyst Coverage
• Corporate Governance
• Email Alerts
• FAQ
• Financial Reports
• Fundamentals
• Image Library
• Information Request
• Investor Events
• SEC Filings
• Presentation Archive
• Press Releases
• Stock Chart
• Stock Quote
• Worth Noting

Current | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Celera Genomics and Celera Diagnostics to Webcast Investor Presentation

ROCKVILLE, MD and ALAMEDA, CA - April 01, 2005

Applera Corporation announced today that the Celera Genomics Group (NYSE:CRA) and Celera Diagnostics, a joint venture of Celera Genomics and Applera’s Applied Biosystems Group (NYSE:ABI), will webcast a meeting with investors visiting Celera Diagnostics’ Alameda offices on April 6, 2005. The meeting is scheduled to last from 9:00 a.m. PT to 11:00 a.m. PT. Kathy Ordoñez, President of Celera Genomics and Celera Diagnostics, Robert Booth, Ph.D., Chief Scientific Officer of Celera Genomics, and Thomas White, Ph.D., Chief Scientific Officer of Celera Diagnostics will provide an overview of the businesses with examples of recent scientific discoveries and developments at Celera Genomics and Celera Diagnostics.

Interested parties may access the live webcast and replay by visiting the Investors & Media section of either the Celera Genomics website at www.celera.com or the Applera website at www.applera.com or the Investors section of the Applied Biosystems website at http://ir.appliedbiosystems.com. It is suggested that participants access the webcast 15 minutes before the start of the live broadcast. The webcast replay will be archived on the Presentations page of the Investors & Media section of each website.

About Applera Corporation
Applera Corporation consists of two operating groups. The Celera Genomics Group is engaged principally in the discovery and development of targeted therapeutics for cancer, autoimmune and inflammatory diseases. Celera Genomics is leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop small molecule therapeutics. It is also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. The Applied Biosystems Group (NYSE:ABI) serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.7 billion during fiscal 2004. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at www.applera.com, or by telephoning 800.762.6923. Information about Celera Genomics is available at www.celera.com.

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.